262 related articles for article (PubMed ID: 26070072)
1. Significant Differences in the Development of Acquired Resistance to the MDM2 Inhibitor SAR405838 between In Vitro and In Vivo Drug Treatment.
Hoffman-Luca CG; Yang CY; Lu J; Ziazadeh D; McEachern D; Debussche L; Wang S
PLoS One; 2015; 10(6):e0128807. PubMed ID: 26070072
[TBL] [Abstract][Full Text] [Related]
2. SAR405838: an optimized inhibitor of MDM2-p53 interaction that induces complete and durable tumor regression.
Wang S; Sun W; Zhao Y; McEachern D; Meaux I; Barrière C; Stuckey JA; Meagher JL; Bai L; Liu L; Hoffman-Luca CG; Lu J; Shangary S; Yu S; Bernard D; Aguilar A; Dos-Santos O; Besret L; Guerif S; Pannier P; Gorge-Bernat D; Debussche L
Cancer Res; 2014 Oct; 74(20):5855-65. PubMed ID: 25145672
[TBL] [Abstract][Full Text] [Related]
3. Novel MDM2 inhibitor SAR405838 (MI-773) induces p53-mediated apoptosis in neuroblastoma.
Lu J; Guan S; Zhao Y; Yu Y; Wang Y; Shi Y; Mao X; Yang KL; Sun W; Xu X; Yi JS; Yang T; Yang J; Nuchtern JG
Oncotarget; 2016 Dec; 7(50):82757-82769. PubMed ID: 27764791
[TBL] [Abstract][Full Text] [Related]
4. SAR405838: A Novel and Potent Inhibitor of the MDM2:p53 Axis for the Treatment of Dedifferentiated Liposarcoma.
Bill KL; Garnett J; Meaux I; Ma X; Creighton CJ; Bolshakov S; Barriere C; Debussche L; Lazar AJ; Prudner BC; Casadei L; Braggio D; Lopez G; Zewdu A; Bid H; Lev D; Pollock RE
Clin Cancer Res; 2016 Mar; 22(5):1150-60. PubMed ID: 26475335
[TBL] [Abstract][Full Text] [Related]
5. Elucidation of Acquired Resistance to Bcl-2 and MDM2 Inhibitors in Acute Leukemia In Vitro and In Vivo.
Hoffman-Luca CG; Ziazadeh D; McEachern D; Zhao Y; Sun W; Debussche L; Wang S
Clin Cancer Res; 2015 Jun; 21(11):2558-68. PubMed ID: 25754349
[TBL] [Abstract][Full Text] [Related]
6. Restoration of p53 using the novel MDM2-p53 antagonist APG115 suppresses dedifferentiated papillary thyroid cancer cells.
Chen H; Luo D; Zhang L; Lin X; Luo Q; Yi H; Wang J; Yan X; Li B; Chen Y; Liu X; Zhang H; Liu S; Qiu M; Yang D; Jiang N
Oncotarget; 2017 Jun; 8(26):43008-43022. PubMed ID: 28498808
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of the MDM2 Inhibitor SAR405838 in Glioblastoma Is Limited by Poor Distribution Across the Blood-Brain Barrier.
Kim M; Ma DJ; Calligaris D; Zhang S; Feathers RW; Vaubel RA; Meaux I; Mladek AC; Parrish KE; Jin F; Barriere C; Debussche L; Watters J; Tian S; Decker PA; Eckel-Passow JE; Kitange GJ; Johnson AJ; Parney IF; Anastasiadis PZ; Agar NYR; Elmquist WF; Sarkaria JN
Mol Cancer Ther; 2018 Sep; 17(9):1893-1901. PubMed ID: 29970480
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of MDM2 Re-Sensitizes Rapamycin Resistant Renal Cancer Cells via the Activation of p53.
Tian X; Dai S; Sun J; Jiang S; Sui C; Meng F; Li Y; Fu L; Jiang T; Wang Y; Su J; Jiang Y
Cell Physiol Biochem; 2016; 39(5):2088-2098. PubMed ID: 27825169
[TBL] [Abstract][Full Text] [Related]
9. Brain Distributional Kinetics of a Novel MDM2 Inhibitor SAR405838: Implications for Use in Brain Tumor Therapy.
Kim M; Laramy JK; Gampa G; Parrish KE; Brundage R; Sarkaria JN; Elmquist WF
Drug Metab Dispos; 2019 Dec; 47(12):1403-1414. PubMed ID: 31619389
[TBL] [Abstract][Full Text] [Related]
10. Synergistic activity and heterogeneous acquired resistance of combined MDM2 and MEK inhibition in KRAS mutant cancers.
Hata AN; Rowley S; Archibald HL; Gomez-Caraballo M; Siddiqui FM; Ji F; Jung J; Light M; Lee JS; Debussche L; Sidhu S; Sadreyev RI; Watters J; Engelman JA
Oncogene; 2017 Nov; 36(47):6581-6591. PubMed ID: 28783173
[TBL] [Abstract][Full Text] [Related]
11. MDM2 Inhibition Sensitizes Prostate Cancer Cells to Androgen Ablation and Radiotherapy in a p53-Dependent Manner.
Feng FY; Zhang Y; Kothari V; Evans JR; Jackson WC; Chen W; Johnson SB; Luczak C; Wang S; Hamstra DA
Neoplasia; 2016 Apr; 18(4):213-22. PubMed ID: 27108384
[TBL] [Abstract][Full Text] [Related]
12. Human glioblastoma multiforme: p53 reactivation by a novel MDM2 inhibitor.
Costa B; Bendinelli S; Gabelloni P; Da Pozzo E; Daniele S; Scatena F; Vanacore R; Campiglia P; Bertamino A; Gomez-Monterrey I; Sorriento D; Del Giudice C; Iaccarino G; Novellino E; Martini C
PLoS One; 2013; 8(8):e72281. PubMed ID: 23977270
[TBL] [Abstract][Full Text] [Related]
13. Reactivation of p53 by MDM2 Inhibitor MI-77301 for the Treatment of Endocrine-Resistant Breast Cancer.
Lu J; McEachern D; Li S; Ellis MJ; Wang S
Mol Cancer Ther; 2016 Dec; 15(12):2887-2893. PubMed ID: 27765850
[TBL] [Abstract][Full Text] [Related]
14. TP53 mutations emerge with HDM2 inhibitor SAR405838 treatment in de-differentiated liposarcoma.
Jung J; Lee JS; Dickson MA; Schwartz GK; Le Cesne A; Varga A; Bahleda R; Wagner AJ; Choy E; de Jonge MJ; Light M; Rowley S; Macé S; Watters J
Nat Commun; 2016 Aug; 7():12609. PubMed ID: 27576846
[TBL] [Abstract][Full Text] [Related]
15. Potent and orally active small-molecule inhibitors of the MDM2-p53 interaction.
Yu S; Qin D; Shangary S; Chen J; Wang G; Ding K; McEachern D; Qiu S; Nikolovska-Coleska Z; Miller R; Kang S; Yang D; Wang S
J Med Chem; 2009 Dec; 52(24):7970-3. PubMed ID: 19928922
[TBL] [Abstract][Full Text] [Related]
16. Reactivation of p53 by novel MDM2 inhibitors: implications for pancreatic cancer therapy.
Azmi AS; Philip PA; Aboukameel A; Wang Z; Banerjee S; Zafar SF; Goustin AS; Almhanna K; Yang D; Sarkar FH; Mohammad RM
Curr Cancer Drug Targets; 2010 May; 10(3):319-31. PubMed ID: 20370686
[TBL] [Abstract][Full Text] [Related]
17. Multiple distinct molecular mechanisms influence sensitivity and resistance to MDM2 inhibitors in adult acute myelogenous leukemia.
Long J; Parkin B; Ouillette P; Bixby D; Shedden K; Erba H; Wang S; Malek SN
Blood; 2010 Jul; 116(1):71-80. PubMed ID: 20404136
[TBL] [Abstract][Full Text] [Related]
18. TP53 mutant MDM2-amplified cell lines selected for resistance to MDM2-p53 binding antagonists retain sensitivity to ionizing radiation.
Drummond CJ; Esfandiari A; Liu J; Lu X; Hutton C; Jackson J; Bennaceur K; Xu Q; Makimanejavali AR; Del Bello F; Piergentili A; Newell DR; Hardcastle IR; Griffin RJ; Lunec J
Oncotarget; 2016 Jul; 7(29):46203-46218. PubMed ID: 27323823
[TBL] [Abstract][Full Text] [Related]
19. Acquisition of p53 mutations in response to the non-genotoxic p53 activator Nutlin-3.
Aziz MH; Shen H; Maki CG
Oncogene; 2011 Nov; 30(46):4678-86. PubMed ID: 21643018
[TBL] [Abstract][Full Text] [Related]
20. MDM2 inhibitor MI-319 in combination with cisplatin is an effective treatment for pancreatic cancer independent of p53 function.
Azmi AS; Aboukameel A; Banerjee S; Wang Z; Mohammad M; Wu J; Wang S; Yang D; Philip PA; Sarkar FH; Mohammad RM
Eur J Cancer; 2010 Apr; 46(6):1122-31. PubMed ID: 20156675
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
